OBJECTIVES: 1) Assess the current status of data disclosure in terms of Medicines Registration and Quality Assurance, Availability of Medicines, Price of Medicine and Polices and Practices concerning the promotion of medicines in Jordan; 2) Disclose the currently available data; 3) Identify where there are gaps in information. METHODS: Using data disclosure survey tool developed by WHO collaborating center in pharmaceutical policy under the Medicines Transparency Intiative that was implemented in Jordan(2008-2009). RESULTS: The disclosure survey results showed that only 20% of the key disclosure data around the four key MeTA components is available and publicly disclosed, while 60% is available but not publicly disclosed and 20% is not available. Most of the unavailable data was related to medicines promotion and standard treatment guidelines polices and practices. Most of polices/laws, regulations, and practices covering medicines registration, quality assurance and pricing are available, disclosed and enforcing by law. The data disclosure process highlightined some challenges in the availability and access to information such as limited access to some data  due to requirement of fees and limited engament of the private sector in disclosing data especially when it comes to utilizationa nd expenditure data. CONCLUSIONS: 1) To  work on establishing a national  committee with authority to monitor adherence to pharmaceutical promotion codes of ethics; 2) To work with related parties on establishing a national committee to develop evidence based standard treatment guidelines; 3) To work with health authorites such as the JFDA to improve accessibility to important data such as updated medicines prices and registration status; and 4) To establish a montoring system in collaboration with related stakholders to update and review the disclosure status in Jordan regularly in order to monitor progress through classifying  data into A, B, and C categories A : available and publicly disclosed B : Available C : Not Available